Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Quality of Life Subcommittee

Executive Summary

The first meeting of the new subcommittee of the Oncologic Drugs Advisory Committee will take place Feb. 10 (1"The Pink Sheet" Dec. 20, 1999, In Brief). The panel will discuss the definition of patient centered outcomes, clinical significance in interpretation of study results and approaches to statistical analysis of data. The meeting will take place at 8:00 a.m. at the Ramada Inn in Bethesda, Md

You may also be interested in...

FDA Quality of Life Subcommittee

FDA appoints new subcommittee to the Oncologic Drugs Advisory Committee to discuss quality of life issues. The committee will be made up of members of the Oncologic Drugs Advisory Committee as well as quality of life experts. Its first meeting is tentatively scheduled for Feb. 10

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts